Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: prospective findings from the Women's Health Initiative Observational Study.
Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: prospective findings from the Women's Health Initiative Observational Study.
复制标题
DOI：
10.1111/j.1532-5415.2008.02121.x
复制
发表时间：
2009-02
影响因子：
6.3
通讯作者：
Women's Health Initiative Observational Study
中科院分区：
文献类型：
--
作者：
Gray SL;LaCroix AZ;Aragaki AK;McDermott M;Cochrane BB;Kooperberg CL;Murray AM;Rodriguez B;Black H;Woods NF;Women's Health Initiative Observational Study
Angiotensin-converting enzyme (ACE) inhibitor medications have the potential to preserve skeletal muscle and thus may be targets to prevent frailty in older adults. Our objective was to examine the associations between current use, duration, and potency of ACE inhibitors and incident frailty in women ages 65 and older who are not frail at baseline. Data are from the Women's Health Initiative Observational Study (WHI-OS), a prospective study conducted at 40 United States clinical centers. Women between the ages of 65-79 years at baseline who were not frail (n=27,378). Current ACE inhibitor use was ascertained through direct inspection of medicine containers at baseline. Components of frailty included: self-reported low physical function/impaired walking; exhaustion; low physical activity; and unintended weight loss between baseline and 3 years of follow-up. Frailty was ascertained through self-reported and physical measurements data at baseline and 3-year clinic contacts. By the three year follow-up, 3950 (14.4%) women had developed frailty. Current ACE inhibitor use had no association with incident frailty (multivariate-adjusted odds ratio (OR)=0.96; 95% confidence interval (CI), 0.82-1.13). Duration and potency of ACE inhibitor use were also not significantly associated with incident frailty. A similar pattern of results was observed when incident cardiovascular disease events were studied as a separate outcome or when the sample was restricted to those with hypertension. Overall, incidence of frailty was similar in current ACE inhibitor users and non-users.
登录
查看更多内容
影响因子：
5.6
作者：
Anderson, GL;Manson, J;Prentice, RL
通讯作者：
Prentice, RL
影响因子：
9.8
作者：
Cahová, M;Vavrinková, H;Kazdova, L
通讯作者：
Kazdova, L
DOI：
10.1111/j.1532-5415.2005.53568.x
发表时间：
2005-11-01
影响因子：
6.3
作者：
Schellenbaum, GD;Smith, NL;Psaty, BM
通讯作者：
Psaty, BM
DOI：
10.1093/gerona/57.5.m326
发表时间：
2002-05-01
影响因子：
5.1
作者：
Visser, M;Pahor, M;Harris, TB
通讯作者：
Harris, TB
影响因子：
6.7
作者：
Cao, Y-J;Mager, D. E.;Abernethy, D. R.
通讯作者：
Abernethy, D. R.